Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Net Cash Flow: 2023-2025

Historic Net Cash Flow for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $30.5 million.

  • CG Oncology's Net Cash Flow rose 67.21% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 94.77%. This contributed to the annual value of $248.8 million for FY2024, which is 411.48% up from last year.
  • Per CG Oncology's latest filing, its Net Cash Flow stood at $30.5 million for Q3 2025, which was up 213.78% from -$26.8 million recorded in Q2 2025.
  • CG Oncology's Net Cash Flow's 5-year high stood at $213.7 million during Q4 2024, with a 5-year trough of -$215.6 million in Q1 2025.
  • Its 3-year average for Net Cash Flow is -$3.9 million, with a median of -$2.0 million in 2023.
  • In the last 5 years, CG Oncology's Net Cash Flow spiked by 10,745.59% in 2024 and then tumbled by 411.58% in 2025.
  • Quarterly analysis of 3 years shows CG Oncology's Net Cash Flow stood at -$2.0 million in 2023, then skyrocketed by 10,745.59% to $213.7 million in 2024, then spiked by 67.21% to $30.5 million in 2025.
  • Its last three reported values are $30.5 million in Q3 2025, -$26.8 million for Q2 2025, and -$215.6 million during Q1 2025.